NIH Clinical Research Studies Listed By Institute of the Principal Investigator

National Cancer Institute (NCI)

335 Protocols (221 Active Accrual of new subjects, 114 Follow-up of previously enrolled subjects)

Active Accrual, Protocols Recruiting New Patients 
* 06-C-0250:
A Phase II Trial of Bevacizumab and Irinotecan for Patients with Recurrent High-Grade Gliomas Immediately Following Tumor Progression After Treatment w/Bevacizumab Alone: A Companion Trial to NCI Study 06-C-0064 (Bevacizumab Alone for Recurrent Gliomas)

* 06-C-0233:
A Phase I Study of the RAF Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772 IND# 69896) in Children with Refractory Solid Tumors or Refractory Leukemias

* 06-C-0227:
Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies

* 06-C-0221:
A Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Advanced Malignancies

* 06-C-0219:
An Exploratory Study of Biologic and Pathophysiologic Effects of Radiation Therapy in Pediatric Patients with Central Nervous System Tumors

* 06-C-0211:
A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance

* 06-C-0204:
A Phase II Randomized Study of the Effect of Zoledronic Acid Versus Observation on Bone Mineral Density of the Lumbar Spine in Women Who Elect to Undergo Surgery that Results in the Removal of Both Ovaries

* 06-C-0200:
A Phase 1 Study of the Safety and Efficacy of GC1008: A Human Anti-Transforming Growth Factor-Beta (TGFBeta) Monoclonal Antibody in Patients with Advanced Renal Cell Carcinoma or Malignant Melanoma

* 06-C-0198:
A Pilot Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity

* 06-C-0177:
Microarray Analysis of the Effect of Cyclosporine Therapy on Gene Expression Patterns in Large Granular Lymphocytic Leukemia

* 06-C-0169:
Phase II Study in Metastatic Melanoma or Kidney Cancer using Autologous Natural Killer Cells Plus Aldesleukin (IL-2) Following a Lymphodepleting Chemotherapy

* 06-C-0164:
A Phase II Study of BAY 43-9006 (Sorafenib) in Combination with Cetuximab (Erbitux™ (Trademark)) in EGFR Expressing Metastatic Colorectal Cancer (CRC)

* 06-C-0152:
Phase I Trial of CEDIRANIB (AZD2171), an Orally Bioavailable Antiangiogenic Agent, in Children and Adolescents with Refractory or Recurrent Solid Tumors or Acute Myelogenous Leukemia

* 06-C-0150:
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for CD25 Positive Hairy Cell Leukemia

* 06-C-0115:
Studies on the Mechanism of Action of High-dose IL-2 in Metastatic Melanoma and Renal Cell Cancer

* 06-C-0112:
A Phase II Clinical Trial of the Histone Deacetylase Inhibitor Valproic Acid in Combination with Temodar and Radiation Therapy in Patients with High Grade Gliomas

* 06-C-0088:
A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan with Venous Filtration via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver

* 06-C-0083:
Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients with Kaposi's Sarcoma

* 06-C-0069:
Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High Risk Melanoma

* 06-C-0064:
A Phase II Trial of Bevacizumab for Patients with Recurrent High-Grade Gliomas

* 06-C-0063:
A Phase I/II Trial of ZD6474 for Patients with Recurrent High-Grade and Progressive Low-Grade Gliomas

* 06-C-0060:
Dermoscopic Diagnosis, Histopathological Correlation, and Cellular Immortalization of Melanocytic Nevi and Primary Cutaneous Melanoma

* 06-C-0051:
AIDS-related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate with Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy

* 06-C-0043:
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral Nerve Sheath Tumors

* 06-C-0014:
Prospective Evaluation of Epigenetic Alterations in Patients with Thoracic Malignancies

* 05-C-0252:
Phase III Randomized Study of R-CHOP v. Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated de Novo Diffuse Large B-Cell Lymphomas

* 05-C-0241:
A Pilot Study of Image Guided Prostate and Pelvic Nodal Irradiation with Intensity Modulated Radiation Therapy (IMRT) in Prostate Cancer

* 05-C-0229:
A Randomized Pilot Phase II Study of Docetaxel alone or in Combination with PANVAC-V (Vaccinia) and PANVAC-F (Fowlpox) in Adults with Metastatic Breast Cancer

* 05-C-0191:
A Phase I Study of Image Guided Dose Escalation with Intensity Modulated Radiation Therapy (IMRT) to Histologically Confirmed Regions of Prostate Cancer

* 05-C-0186:
A Pilot Trial of Oral Topotecan for the Treatment of Refractory Advanced Solid Neoplasms Expressing HIF-1 Alpha

* 05-C-0185:
Phase II Study of the Efficacy and Toxicity of Ontak (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

* 05-C-0170:
Randomized Phase II Study of Dose-Adjusted EPOCH-Rituximab-Bortezomib (EPOCH-R-B) Induction Followed by Bortezomib Maintenance versus Observation in Untreated Mantle Cell Lymphoma with Microarray Profiling and Proteomics

* 05-C-0150:
A Study of Central Nervous System Disease in Pediatric HIV in the HAART Era

* 05-C-0137:
A Phase II Trial of Tamoxifen and Bortezomib in Patients with Recurrent High-Grade Gliomas

* 05-C-0049:
Phase II Study of Bay 43-9006 (Sorafenib) with Evaluation of RAS Signal Pathway in Patients with Relapsed Non-Small Cell Lung Cancer

* 05-C-0044:
Immunologic Studies of Tumors of the Pancreas

* 05-C-0010:
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum

* 04-C-0281:
Natural History Study of Clinical and Biological Factors Determining Outcomes in Chronic Graft-Versus-Host Disease

* 04-C-0275:
Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's Disease with Laboratory and Clinical Correlates of Disease Activity

* 04-C-0274:
Follow-Up of Study Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer

* 04-C-0273:
A Phase II Study of Hepatic Arterial Infusion of Melphalan with Venous Filtration via Peripheral Hepatic Perfusion (PHP) for Unresectable Primary and Metastatic Cancers of the Liver

* 04-C-0257:
A Phase II Trial of Docetaxel, Thalidomide, Prednisone and Bevacizumab in Patients with Androgen-Independent Prostate Cancer

* 04-C-0232:
A Multi-Institutional Study of Proteomic Evaluation of Epithelial Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer Patients in First Clinical Remission: Development of a Protein Fingerprint Profile of Relapse

* 04-C-0200:
Urinary and Serum VEGF and MMP Levels in Patients Receiving Radiation Therapy for Glioblastoma Multiforme: Prospective Determination of a Predictive Value for Recurrence

* 04-C-0177:
A Pilot Study of Tc-94m Sestamibi PET MDR Imaging

* 04-C-0173:
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas

* 04-C-0165:
Medical Oncology Care in the NCI, Center for Cancer Research

* 04-C-0155:
Barrett's Esophagus Early Detection Study

* 04-C-0142:
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Cutaneous T-Cell Lymphomas

* 04-C-0131:
Allogeneic Breast Protocol 2: Phase I Trial of T cell Exchange with Th2/Tc2 Cells for Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for Metastatic Breast Cancer

* 04-C-0121:
A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia

* 04-C-0116:
T-Cell Depleted, Reduced-Intensity Allogeneic Stem Cell Transplantation from Haploidentical Related Donors for Hematologic Malignancies (HAPLO Part A)

* 04-C-0102:
Hematologic Malignancy Biology Study

* 04-C-0089:
Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward The IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia

* 04-C-0081:
Pathogenesis and Course of Cutaneous T-Cell Lymphoma

* 04-C-0055:
Allogeneic HSCT without Preparative Chemotherapy or with Low-Intensity Preparative Chemotherapy using Sirolimus and Sirolimus-Generated Donor Th2 Cells for Therapy of Refractory Leukemia, Lymphoma, Myeloma, or Myelodysplastic Syndrome

* 04-C-0049:
A Phase I/II Study of an Antitumor Vaccination Using Alpha (1,3) Galactosyltransferase Expressing Allogeneic Tumor Cells in Patients with Refractory or Recurrent Non-Small Cell Lung Cancer

* 04-C-0001:
Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing's Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma

* 03-C-0304:
Pilot Trial of Alemtuzumab and Dose-Adjusted Epoch in Chemotherapy Naive Aggressive T and NK-Cell Lymphomas

* 03-C-0278:
A Comparative Study of Pediatric CNS Tumor Activity as Assessed by [18]F-FDG PET Imaging and Proton Magnetic Resonance Spectroscopic Imaging ([1]H-MRSI)

* 03-C-0277:
Cell Harvest and Preparation for Surgery Branch Adoptive Cell Therapy Protocols

* 03-C-0241:
The Natural History of Childhood Malignancies Treated with Radiation Therapy

* 03-C-0216:
A Groupwide Biology and Banking Study for Ewing Sarcoma: Children's Oncology Group

* 03-C-0194:
Phase II Study of the Efficacy and Toxicity of Campath-1H in the Therapy of Adult T-Cell Leukemia

* 03-C-0110:
Phase II Study of Intravenous Recombinant Humanized Anti-Vascular Endothelial Cell Growth Factor Antibody (Bevacizumab) in Classical (HIV-Negative) and in AIDS-Associated Kaposi's Sarcoma

* 03-C-0066:
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer

* 03-C-0040:
A Multicenter Phase I-II Study of Tumor Vaccine Following Chemotherapy in Patients with Metastatic Breast Cancer Untreated with Chemo/Radiation in the Previous 18 Months: Vaccine-Induced Bias of T-Cell Repertoire Reconstitution After T-Cell Re-Infusion

* 03-C-0030:
Phase I Trial of Romidepsin Given on Days One, Three, and Five in Patients with Thyroid and Other Advanced Cancers

* 02-C-0313:
Cancer Risk in Xeroderma Pigmentosum Heterozygotes

* 02-C-0284:
A Pilot study of Ipilimumab (MDX-CTLA-4, MDX-010) in Lymphoma

* 02-C-0259:
Pilot Study of Allogeneic/Syngeneic Blood Stem Cell Transplantation in Patients with High-Risk and Recurrent Pediatric Sarcomas

* 02-C-0258:
Acquisition of Blood, Bone Marrow, Tumor, or Tissue Samples

* 02-C-0212:
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer

* 02-C-0211:
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

* 02-C-0210:
Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Blood and Lymph Node Malignancy

* 02-C-0205:
Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion with or without Concurrent Celecoxib in Subjects with Pulmonary and Pleural Malignancies

* 02-C-0193:
A Phase II Study Of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) In Children With Diffuse Pontine Gliomas

* 02-C-0186:
Eligibility Screening of Patients with CNS Tumors for NCI Clinical Research Protocols

* 02-C-0179:
Collection of Blood from Patients with Cancer

* 02-C-0178:
Multidisciplinary Etiologic Study of Familial Testicular Cancer

* 02-C-0159:
The Birt Hogg-Dube Syndrome: Identification of the Disease Gene and Characterization of the Predisposition of Renal Cancer

* 02-C-0149:
A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer

* 02-C-0144:
Establishment of Normal High Risk Breast Epithelial Cell Cultures, and A High Risk Cell Line and Tissue Repository from Breast Tissue from Women at High Risk of Breast Cancer

* 02-C-0140:
A Prospective National Study to Molecularly and Genetically Characterize Human Gliomas: The Glioma Molecular Diagnostic Initiative

* 02-C-0130:
A Phase II Clinical Trial of BMS-247550 (NSC710428), an Epothilone B Analog, in Renal Cell Carcinoma

* 02-C-0077:
Characterization of High Risk Breast Duct Epithelium by Cytology, Breast Duct Endoscopy, and cDNA Gene Expression Profile

* 02-C-0064:
Collection of Peripheral Blood and/ or Urine From Patients Undergoing Radiation Therapy

* 02-C-0052:
Etiologic Investigation of Cancer Susceptibility in Inherited Bone Marrow Failure Syndromes: A Natural History Study

* 02-C-0031:
Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients with Refractory Solid Tumors and Leukemias

* 01-C-0158:
Protocol to Assess Vascularity in Kaposi's Sarcoma Lesions Utilizing Non-Invasive Imaging Techniques

* 01-C-0157:
Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI), Pediatric Oncology Branch (POB) Clinical Research Protocols

* 01-C-0144:
Surveillance of Invasive Fungal Infections in Bone Marrow/Stem Cell and Solid Organ Transplantation Recipients and Other Immunocompromised Patients: A Prospective Study

* 01-C-0129:
Eligibility Screening and Tissue Procurement for the National Cancer Institute (NCI) Center for Cancer Research (CCR) Clinical Protocols

* 01-C-0125:
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies

* 01-C-0104:
A Phase I Study of Concomitant Therapy with Proteasome Inhibitor PS-341 and Radiation in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

* 01-C-0070:
Evaluation of the Natural History of Patients with Tumors of the Central Nervous System

* 01-C-0038:
Collection of Blood, Bone Marrow, Tumor, or Tissue Samples from Patients with HIV Infection, KSHV Infection, Viral-related Pre-malignant Lesions, and/or Cancer

* 01-C-0030:
Short-Course EPOCH-Rituximab for Untreated CD-20+ HIV-Associated Lymphomas

* 00-C-0181:
Evaluation for NCI Radiation Oncology Branch Clinical Research Protocols

* 00-C-0121:
A Phase I Investigation of IL-12/Pulse IL-2 in Adults with Advanced Solid Tumors

Previous 100 Protocols

Next -200 Protocols

Command Menu Bar

Search The Studies | Help | Questions |
Clinical Center Home | NIH Home

Clinical Center LogoNational Institutes of Health Clinical Center
Bethesda, Maryland 20892. Last update: 01/30/2009
Search The Studies Help Questions
Search The Studies Help Questions